Journé F, Dumon J-C, Kheddoumi N, Fox J, Laïos I, Leclercq G, Body J-J
Laboratory of Endocrinology, Bone Diseases and Breast Cancer Research, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Bone. 2004 Aug;35(2):479-88. doi: 10.1016/j.bone.2004.03.021.
Skeleton is the most common organ targeted by breast cancer cells, especially from estrogen receptor alpha (ER)-positive neoplasms. Metastatic cells can stimulate directly or indirectly osteoclast-mediated bone resorption. Tumor-induced osteolysis is often extensive and leads to the release of large quantities of calcium. Metastatic cancer cells can be thus exposed to high calcium concentrations (40 mM has been reported at the resorption site). However, the effects of Ca2+ on breast cancer cells have been minimally examined. We showed that 20-mM extracellular Ca2+ induced a downregulation of ER protein in MCF-7 cells and caused ER-mediated transactivation of a reporter gene by 55 +/- 10% (mean +/- SD) in MVLN cells (MCF-7 cells stably transfected with ERE and luciferase reporter gene). Moreover, 3 mM Ca2+ increased progesterone receptor (PgR) expression by 45 +/- 8%. Mg2+ tested at up to 20 mM did not exert any effects, while 17beta-estradiol downregulated ER, transactivated the reporter gene, and enhanced PgR expression. The pure antiestrogen ICI 182,780 was able to abrogate the transactivation of the reporter gene and the increase in PgR levels induced by Ca2+, indicating that Ca2+ may exert a weak and specific estrogenic effect in MCF-7 cells. Ca2+ effects on ER probably start at the cell membrane level since a large Ca2+ influx caused by the ionophore A23187 failed to activate ER. We have thus studied the involvement of the membrane calcium-sensing receptor (CaR) that is known to be expressed notably in MCF-7 cells. We first tested the effects of a specific activator of CaR. Exposure to 10(-4) M calcimimetic NPS R-467 mirrored the changes observed with extracellular Ca2+ by inducing a marked decrease in ER protein levels, increasing the transcriptional activity of ER (67 +/- 12%) and stimulating PgR expression (41 +/- 4%). As expected, the NPS S-467 isomer was less effective. Furthermore, a highly selective CaR antagonist partly suppressed the downregulation of ER as well as transactivation of the reporter gene induced by Ca(2+). Our results suggest that the effects of extracellular Ca2+ on ER expression and activity are mediated, at least in part, by the CaR. In summary, calcium released during the process of metastatic bone destruction could modulate the functions of the estrogen receptor, a key receptor involved in breast cancer cells growth and function, and thus participate in the pathogenesis of tumor-induced osteolysis.
骨骼是乳腺癌细胞最常靶向的器官,尤其是来自雌激素受体α(ER)阳性肿瘤的细胞。转移细胞可直接或间接刺激破骨细胞介导的骨吸收。肿瘤诱导的骨溶解通常广泛,导致大量钙的释放。因此,转移癌细胞可能暴露于高钙浓度(据报道,吸收部位的钙浓度可达40 mM)。然而,Ca2+对乳腺癌细胞的影响研究甚少。我们发现,20 mM的细胞外Ca2+可导致MCF-7细胞中ER蛋白下调,并使MVLN细胞(稳定转染ERE和荧光素酶报告基因的MCF-7细胞)中报告基因的ER介导的反式激活增加55±10%(平均值±标准差)。此外,3 mM Ca2+可使孕激素受体(PgR)表达增加45±8%。高达20 mM的Mg2+未产生任何影响,而17β-雌二醇可下调ER、激活报告基因并增强PgR表达。纯抗雌激素药物ICI 182,780能够消除报告基因的反式激活以及Ca2+诱导的PgR水平升高,表明Ca2+可能在MCF-7细胞中发挥微弱且特异的雌激素样作用。Ca2+对ER的影响可能始于细胞膜水平,因为离子载体A23187引起的大量Ca2+内流未能激活ER。因此,我们研究了已知在MCF-7细胞中显著表达的膜钙敏感受体(CaR)的作用。我们首先测试了CaR特异性激活剂的作用。暴露于10(-4) M的拟钙剂NPS R-467可诱导ER蛋白水平显著降低、增加ER的转录活性(67±12%)并刺激PgR表达(41±4%),这与细胞外Ca2+引起的变化相似。正如预期的那样,NPS S-467异构体的效果较差。此外一种高度选择性的CaR拮抗剂可部分抑制Ca2+诱导的ER下调以及报告基因的反式激活。我们的结果表明,细胞外Ca2+对ER表达和活性的影响至少部分是由CaR介导的。总之,转移性骨破坏过程中释放的钙可调节雌激素受体的功能,雌激素受体是参与乳腺癌细胞生长和功能的关键受体,从而参与肿瘤诱导的骨溶解的发病机制。